Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Nippon Kayaku’s Novel Paclitaxel Form in Breast Cancer PII after PIII Miss
February 22, 2018
- Takeda, Wave Ink Antisense Pact for Neurological Diseases
February 22, 2018
- Novartis Japan Chief on Rare Paternity Leave, Looks to Lead by Example
February 22, 2018
- Bristol-Myers Japan Taps Ex-AZ Exec Hashigami as Development Chief
February 21, 2018
- Taniuchi Appointed as Santen President and COO
February 21, 2018
- Aducanumab Trial Tweak “Common Decision” to Boost Statistical Confidence: Biogen CEO
February 21, 2018
- Seikagaku to Run Add’l PIII for Lumbar Disc Herniation Drug in US
February 20, 2018
- Fujifilm Starts Japan PII for Radiopharmaceutical in Pheochromocytoma
February 20, 2018
- Dovobet Gel Wins Japan Approval: LEO/Kyowa Kirin
February 20, 2018
- Medical System Network Taps into Generic Business via Its Dispensing Pharmacy Chains, Aiming at Future Expansion
February 20, 2018
- Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
February 20, 2018
- Takeda to Revamp Sales Offices as Japan Shifts to Community-Based Care System
February 20, 2018
- Lenvima OK’ed for UK Health Coverage in Thyroid Cancer
February 19, 2018
- Oncolys Invests in US Immuno-Oncology Startup
February 19, 2018
- Sumitomo Dainippon Halts Development of FXR Agonist in Japan, South Korea
February 16, 2018
- Daiichi Sankyo Files Mirogabalin in Japan for PNP
February 16, 2018
- Global Brands Drive Otsuka’s Pharma Sales in 2017
February 15, 2018
- Astellas Picks Up US Upstart, Grabs Full Access to Universal Donor Cell Technology
February 15, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
- Teijin, SanBio Terminate License Agreement for Stroke Treatment; Development and Marketing Rights to Revert to SanBio
February 15, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…